Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim ± small-molecule TPO receptor agonists for cancer treatment-induced thrombocytopenia
ChiCTR2400094696Phase 2Not yet recruiting
- Sponsor
- Sheyang County People's Hospital
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in Thrombocytopenia, sponsored by Sheyang County People's Hospital. Primary endpoint: Proportion of patients who respond within 7 days of treatment. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2400094696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094696.